No Data
No Data
Ferment Launches $20M Studio Fund to Accelerate Biotech Solutions Across Vital Industries
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $6
Ginkgo Bioworks Price Target Lowered to $6 From $7 at BTIG
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Ginkgo Bioworks's Restructuring Starting to Bear Fruit, Says TD Cowen
TechTrek Invest : I'm buying little and often.